COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Older adults are at the highest risk of complications and severe illness for 2019-nCoV infections. Hydroxychloroquine (HCQ), an emerging chemoprophylaxis, which holds clinical and mechanistic plausibility, will help to reduce disease incidence and mitigate disease severity across in-patient settings. This study is designed to assess the safety and efficacy of post-exposure prophylaxis with hydroxychloroquine (HCQ) for the prevention of Coronavirus Infectious Disease-19 (COVID-19) in high-risk older individuals in long-term and specialized care.
Epistemonikos ID: 01fa72e8bf943e9f3e327d659d9ae5ac983889e6
First added on: May 22, 2020